Irbesartán Aurovitas

Irbesartan, the active ingredient in Irbesartán Aurovitas, is a Angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension and diabetic nephropathy in adults. GNH USA supplies Irbesartán Aurovitas as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to control blood pressure and protect kidney function.

Hypertension: lowers elevated blood pressure to reduce cardiovascular risk. Diabetic nephropathy: slows progression of kidney damage in patients with type‑2 diabetes. Proteinuria in diabetes: reduces urinary protein excretion, indicating renal protection.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach or urge to vomit. - Diarrhea: loose stools occurring intermittently. - Elevated serum potassium: mild hyperkalaemia detected in blood tests.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat. - Severe hypotension: sudden, marked drop in blood pressure. - Acute kidney injury: rapid decline in renal function. - Hepatic injury: abnormal liver enzyme elevations. - Myocardial infarction: rare occurrence of heart attack.

Before starting therapy, patients should be evaluated for renal function, electrolyte balance, and hepatic status.

Monitor blood pressure regularly: adjust dose to achieve target levels. Assess renal function: check serum creatinine and eGFR periodically. Check serum potassium: avoid hyperkalaemia, especially with potassium‑sparing agents. Use caution in hepatic impairment: dose may need adjustment. Avoid use in pregnancy: potential fetal toxicity. Store at room temperature: keep in original pack, protect from moisture and light.

Irbesartan may interact with several medicines that affect the renin‑angiotensin system or renal handling of electrolytes.

Major Interactions (Avoid): - Aliskiren (in patients with diabetes): combined use can increase renal risk. - Potassium‑sparing diuretics (e.g., spironolactone): may cause dangerous hyperkalaemia. - ACE inhibitors: concurrent use raises risk of hyperkalaemia and renal dysfunction.

Moderate Interactions (Monitor Closely): - NSAIDs: can blunt antihypertensive effect and impair renal function. - Lithium: irbesartan may raise lithium concentrations, requiring level monitoring.